ATE542816T1 - Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors - Google Patents

Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Info

Publication number: ATE542816T1
Authority: AT; Austria
Prior art keywords: dopamine; modulators; receptor; derivatives
Prior art date: 2004-02-23

Application number

AT08169935T

Other languages

English (en)

Inventor

Luca Arista

Giorgio Bonanomi

Anna Maria Capelli

Federica Damiani

Fabio Romano Di

Gabriella Gentile

Dieter Hamprecht

Fabrizio Micheli

Luca Tarsi

Giovanna Tedesco

Silvia Terreni

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-23

Filing date

2005-02-21

Publication date

2012-02-15

2004-02-23 Priority claimed from GB0403990A external-priority patent/GB0403990D0/en

2004-02-24 Priority claimed from GB0404083A external-priority patent/GB0404083D0/en

2004-07-30 Priority claimed from GB0417120A external-priority patent/GB0417120D0/en

2005-02-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542816T1 publication Critical patent/ATE542816T1/de

Links

102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
108090000525 Dopamine D3 Receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT08169935T 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors ATE542816T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0403990A GB0403990D0 (en)	2004-02-23	2004-02-23	Compounds
GB0404083A GB0404083D0 (en)	2004-02-24	2004-02-24	Compounds
GB0417120A GB0417120D0 (en)	2004-07-30	2004-07-30	Compounds

Publications (1)

Publication Number	Publication Date
ATE542816T1 true ATE542816T1 (de)	2012-02-15

Family

ID=34890800

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT05707610T ATE451364T1 (de)	2004-02-23	2005-02-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AT08169935T ATE542816T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT05707610T ATE451364T1 (de)	2004-02-23	2005-02-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Country Status (25)

Country	Link
US (3)	US7855298B2 (de)
EP (3)	EP2070922B1 (de)
JP (1)	JP4960217B2 (de)
KR (1)	KR101143718B1 (de)
CN (1)	CN1946714B (de)
AR (1)	AR047890A1 (de)
AT (3)	ATE451364T1 (de)
AU (2)	AU2005215918C1 (de)
BR (1)	BRPI0507945A (de)
CA (1)	CA2557115C (de)
CY (3)	CY1109854T1 (de)
DE (1)	DE602005018190D1 (de)
DK (3)	DK2060570T3 (de)
ES (2)	ES2380990T3 (de)
HR (3)	HRP20100114T1 (de)
IL (1)	IL177184A0 (de)
MA (1)	MA28438B1 (de)
NO (1)	NO20064309L (de)
PE (1)	PE20051173A1 (de)
PL (3)	PL1745040T3 (de)
PT (3)	PT2060570E (de)
RU (1)	RU2434011C2 (de)
SI (3)	SI2060570T1 (de)
TW (1)	TW200538113A (de)
WO (1)	WO2005080382A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE451364T1 (de) *	2004-02-23	2009-12-15	Glaxo Group Ltd	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
GB0507602D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en)	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
ATE484502T1 (de)	2005-06-14	2010-10-15	Glaxo Group Ltd	Neue verbindungen
GB0512099D0 (en) *	2005-06-14	2005-07-20	Glaxo Group Ltd	Compounds
WO2007006117A1 (en) *	2005-07-13	2007-01-18	Nicogen Inc.	Novel cyp2a6 inhibitors
AU2006275870B2 (en) *	2005-07-27	2013-01-10	Otsuka America Pharmaceutical, Inc.	Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
ATE487715T1 (de) *	2005-08-22	2010-11-15	Glaxo Group Ltd	Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
GB0517191D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AU2007233715A1 (en)	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors
GB0703387D0 (en) *	2007-02-21	2007-03-28	Glaxo Group Ltd	Novel compounds
GB0607899D0 (en) *	2006-04-03	2006-05-31	Glaxo Group Ltd	Process for preparing heterocyclic derivatives
WO2007113258A1 (en) *	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
WO2007113260A1 (en)	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0608452D0 (en) *	2006-04-27	2006-06-07	Glaxo Group Ltd	Novel compounds
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2167083B1 (de) *	2007-06-06	2015-10-28	Euthymics Bioscience, Inc.	1- heteroaryl-3-azabicyclo[3.1.0]hexane, verfahren zu ihrer herstellung und ihre verwendung als medikamente
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719234D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
GB0719235D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
CA2728226A1 (en)	2008-06-24	2010-01-21	Codexis, Inc.	Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
BRPI0919004A2 (pt) *	2008-09-22	2019-09-24	Cayman Chem Co	composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
MX2012000231A (es) *	2009-06-26	2012-03-07	Panacea Biotec Ltd	Nuevos aza-biciclo-hexanos.
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160279098A1 (en) *	2013-11-11	2016-09-29	Euthymics Bioscience, Inc.	Novel methods
EP3331886B1 (de)	2015-08-05	2020-07-15	Indivior UK Limited	Dopamin-d3-rezeptorantagonisten mit bicycloeinheit
WO2019146740A1 (ja)	2018-01-26	2019-08-01	塩野義製薬株式会社	ドーパミンｄ３受容体拮抗作用を有する環式化合物
CA3187566A1 (en)	2020-06-22	2021-12-30	Corcept Therapeutics Incorporated	Quaternary indazole glucocorticoid receptor antagonists
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CA3243547A1 (en)	2021-12-21	2023-06-29	Corcept Therapeutics Incorporated	INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS
US12098144B2 (en)	2021-12-21	2024-09-24	Corcept Therapeutics Incorporated	Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI274750B (en) *	1999-01-12	2007-03-01	Abbott Gmbh & Co Kg	Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) *	2000-06-23	2000-08-16	Pfizer Ltd	Heterocycles
CN1254474C (zh) *	2000-11-14	2006-05-03	史密斯克莱·比奇曼公司	作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
DE60226161T2 (de)	2001-10-22	2009-07-02	Pfizer Products Inc., Groton	3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
AR040847A1 (es) *	2002-08-09	2005-04-20	Astrazeneca Ab	1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
ATE451364T1 (de) *	2004-02-23	2009-12-15	Glaxo Group Ltd	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
ATE484502T1 (de)	2005-06-14	2010-10-15	Glaxo Group Ltd	Neue verbindungen
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
ATE487715T1 (de) *	2005-08-22	2010-11-15	Glaxo Group Ltd	Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AU2007233715A1 (en)	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds

2005
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 EP EP08169934A patent/EP2070922B1/de not_active Expired - Lifetime
- 2005-02-21 EP EP08169935A patent/EP2060570B1/de not_active Expired - Lifetime
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 EP EP05707610A patent/EP1745040B9/de not_active Expired - Lifetime
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown

Also Published As

Publication number	Publication date
EP1745040B1 (de)	2009-12-09
CA2557115A1 (en)	2005-09-01
US20100152195A1 (en)	2010-06-17
HRP20110781T1 (hr)	2011-11-30
SI2070922T1 (sl)	2011-12-30
CY1113029T1 (el)	2016-04-13
US8263782B2 (en)	2012-09-11
IL177184A0 (en)	2006-12-10
HK1103016A1 (en)	2007-12-14
EP2060570A2 (de)	2009-05-20
PE20051173A1 (es)	2006-02-14
ES2337590T3 (es)	2010-04-27
RU2434011C2 (ru)	2011-11-20
ES2380990T3 (es)	2012-05-22
PT2060570E (pt)	2012-05-07
PT2070922E (pt)	2011-11-24
EP1745040B9 (de)	2010-06-02
CA2557115C (en)	2012-10-02
PL2070922T3 (pl)	2012-01-31
JP2007523208A (ja)	2007-08-16
EP1745040A1 (de)	2007-01-24
CN1946714B (zh)	2011-06-15
DE602005018190D1 (de)	2010-01-21
DK2060570T3 (da)	2012-04-30
KR101143718B1 (ko)	2012-07-05
CY1112011T1 (el)	2015-11-04
NO20064309L (no)	2006-11-23
PT1745040E (pt)	2010-03-08
ATE451364T1 (de)	2009-12-15
PL2060570T3 (pl)	2012-06-29
HRP20100114T1 (hr)	2010-04-30
AU2009212887A1 (en)	2009-09-24
EP2070922A1 (de)	2009-06-17
CN1946714A (zh)	2007-04-11
ATE520686T1 (de)	2011-09-15
HRP20120281T1 (hr)	2012-04-30
AU2005215918C1 (en)	2010-01-21
DK2070922T3 (da)	2011-11-28
BRPI0507945A (pt)	2007-07-24
MA28438B1 (fr)	2007-02-01
TW200538113A (en)	2005-12-01
DK1745040T3 (da)	2010-04-12
SI2060570T1 (sl)	2012-05-31
EP2060570A3 (de)	2009-06-03
EP2060570B1 (de)	2012-01-25
KR20060127991A (ko)	2006-12-13
PL1745040T3 (pl)	2010-05-31
AU2005215918A1 (en)	2005-09-01
AR047890A1 (es)	2006-03-01
JP4960217B2 (ja)	2012-06-27
US20100160336A1 (en)	2010-06-24
WO2005080382A1 (en)	2005-09-01
AU2005215918B2 (en)	2009-06-11
EP2070922B1 (de)	2011-08-17
SI1745040T1 (sl)	2010-04-30
US8283474B2 (en)	2012-10-09
RU2006133909A (ru)	2008-03-27
US20070142438A1 (en)	2007-06-21
US7855298B2 (en)	2010-12-21
CY1109854T1 (el)	2014-09-10

Publication	Publication Date	Title
ATE520686T1 (de)	2011-09-15	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
DE122012000018I1 (de)	2012-06-06	Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
ATE543808T1 (de)	2012-02-15	5,6-ring-annelierte indolderivate und ihre verwendung
DE602005027307D1 (de)	2011-05-19	Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE520681T1 (de)	2011-09-15	N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE450517T1 (de)	2009-12-15	Isoxazolinderivate und ihre verwendung als herbizide
ATE473214T1 (de)	2010-07-15	2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
ATE440093T1 (de)	2009-09-15	1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE432975T1 (de)	2009-06-15	Flüssigwaschmittel und ihre verwendung
ATE454377T1 (de)	2010-01-15	2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE400571T1 (de)	2008-07-15	Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
ATE478059T1 (de)	2010-09-15	Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE428710T1 (de)	2009-05-15	Substituierte phenylaminothiazole und ihre verwendung
DE602004010426D1 (de)	2008-01-10	Mikrobizide zusammensetzungen und ihre verwendung
ATE432701T1 (de)	2009-06-15	Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
ATE518834T1 (de)	2011-08-15	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE392416T1 (de)	2008-05-15	Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE602004021384D1 (de)	2009-07-16	Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
DE602006009804D1 (de)	2009-11-26	Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5
ATE513817T1 (de)	2011-07-15	Pyrimidinderivate und ihre verwendung als pestizide
ATE486070T1 (de)	2010-11-15	Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
ATE442366T1 (de)	2009-09-15	Oxazolidinonderivate und ihre verwendung als antibiotika
DE602006009296D1 (de)	2009-10-29	Oligopeptide und ihre verwendung
DE602006016258D1 (de)	2010-09-30	4h-1,2,4-triazin-5-on-derivate, ihre herstellung und ihre verwendung als alpha-7-nikotin-acetylcholin-rezeptoren